Justina Tavana is a doctoral candidate at BYU who was born and raised in Samoa. She's one of several scientists developing Alzheimer's tests for Utah Pacific Islanders in their native languages as they work to address a public health gap.
PROVO — A Brigham Young University researcher is studying Alzheimer's disease among a group that is rarely included in testing.
"In a national Alzheimer's DNA database, only 17 DNA samples out of 45,000 were from these populations. Studying the disease was also difficult because diagnostic tools and educational materials had never been translated or adapted for Samoan, Tongan and other languages," the statement also said. "A lot of these people have lived here in the states, speak English perfectly," Tavana said. "But it makes such a difference when they walk in and see people from their communities, and people that can speak their languages."The team has held brain health events in the U.S. — including Utah where some 50,000 Pacific Islanders reside — and American Samoa.
Indonesia Berita Terbaru, Indonesia Berita utama
Similar News:Anda juga dapat membaca berita serupa dengan ini yang kami kumpulkan dari sumber berita lain.
Big 12 coaches give their first impressions of BYU footballFrom memories of LaVell Edwards to being upset with late-night travel, here is what the Big12 thinks of BYU in its first year in the league.
Baca lebih lajut »
Alzheimer's disease is more prevalent in these parts of the USA new study looked into the prevalence of Alzheimer's disease by county.
Baca lebih lajut »
This Type of Exercise May Prevent Alzheimer’s Disease, Study FindsResistance Training May Prevent or Delay Alzheimer’s Disease, Study Suggests
Baca lebih lajut »
Second Alzheimer's drug in pipeline can slow the disease by a few months but with safety riskNew research shows another experimental Alzheimer's drug can modestly slow patients' inevitable worsening.
Baca lebih lajut »
Second Alzheimer's drug in pipeline can slow the disease by a few months but with safety riskAnother experimental Alzheimer's drug can modestly slow patients' inevitable worsening — by about four to seven months, researchers reported Monday.
Baca lebih lajut »
Second Alzheimer's drug in pipeline can slow the disease by a few months but with safety riskNew research shows another experimental Alzheimer's drug can modestly slow patients' inevitable worsening.
Baca lebih lajut »